## CAM TElaims

- 1. A mammalian lung surfactant composition consisting essentially of dipalmitoyl phosphatidylcholine in admixture with a fatty alcohol.
- 5 2. The composition of claim 1 wherein the fatty alcohol has from about 14 to 18 carbon atoms.
- 3. The composition of claim 2 wherein the fatty alcohol is hexadecanol.
  - 4. The composition of claim 2 wherein the fatty alcohol is oleic alcohol.
- 15 5. The composition of claim 1 wherein the dipalmitoyl phosphotidyl choline constitutes a major percentage by weight of the composition and wherein the fatty alcohol constitutes a minor percentage.
- 20 6. The composition of claim 5 wherein the fatty alcohol is present in the range of about 6 to 18% by weight and the dipalmitoyl phosphatidyl choline is present in the range of about 82 to 94% by weight.

- 7. A composition for administration into mammalian alveolar spaces comprising a suspension of dipalmitoyl phosphatidyl choline and hexadecanol in saline solution.
- 8. A method for treating respiratory distress syndrome in mammals wherein natural lung surfactant normally produced by the mammal is absent or deficient, comprising introducing into the alveolar spaces a quantity of a composition consisting essentially of a major amount of 1,2 dipalmitoyl-sn-3-glycerophosphoryl choline in admixture with a minor amount of a fatty alcohol.
- 9. The method of claim 8 wherein the 15 fatty alcohol is n-hexadecan-1-ol.

